Invivyd (NASDAQ:IVVD) CFO William Duke Sells 22,355 Shares of Stock

Invivyd, Inc. (NASDAQ:IVVD) CFO William Duke sold 22,355 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $0.72, for a total value of $16,095.60. Following the completion of the transaction, the chief financial officer directly owned 187,362 shares in the company, valued at $134,900.64. This trade represents a 10.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Invivyd Trading Up 17.2%

IVVD traded up $0.13 during trading on Tuesday, hitting $0.87. 7,732,095 shares of the company’s stock traded hands, compared to its average volume of 3,061,089. The stock has a market capitalization of $255.75 million, a price-to-earnings ratio of -2.63 and a beta of 0.71. The company’s 50 day simple moving average is $0.77 and its two-hundred day simple moving average is $1.23. Invivyd, Inc. has a 12-month low of $0.48 and a 12-month high of $3.07.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The business had revenue of $14.29 million during the quarter, compared to analysts’ expectations of $14.40 million. Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%. On average, equities analysts expect that Invivyd, Inc. will post -0.52 EPS for the current year.

Key Invivyd News

Here are the key news stories impacting Invivyd this week:

• Neutral Sentiment: Robert D. Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold shares at prices of approximately $0.72 or $0.84. The sales reduced each insider’s direct holdings by roughly 9% to 11%. SEC insider transaction filing
• Neutral Sentiment: The filings state that the transactions were made to cover tax-withholding obligations tied to the vesting of equity awards. Because the sales were not described as discretionary reductions or based on a negative outlook, they are less concerning than open-market sales intended to exit positions. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by multiple insiders may nevertheless create a modest overhang for Invivyd stock, particularly given the company’s small market capitalization and recent elevated trading volume. However, the disclosed tax-related purpose limits the bearish signal.

Wall Street Analyst Weigh In

Several research firms have issued reports on IVVD. Wall Street Zen cut shares of Invivyd from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. BTIG Research reiterated a “buy” rating on shares of Invivyd in a research note on Tuesday, July 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Invivyd in a report on Friday, July 24th. Finally, HC Wainwright restated a “buy” rating on shares of Invivyd in a research report on Tuesday. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Invivyd currently has an average rating of “Hold” and a consensus target price of $8.00.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Invesco Ltd. boosted its position in Invivyd by 190.6% in the first quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock worth $66,000 after purchasing an additional 71,485 shares during the last quarter. AQR Capital Management LLC increased its position in shares of Invivyd by 2,051.0% during the 1st quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock valued at $249,000 after purchasing an additional 391,617 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Invivyd during the 2nd quarter valued at about $158,000. Jane Street Group LLC bought a new position in shares of Invivyd in the 2nd quarter worth approximately $147,000. Finally, Vanguard Group Inc. lifted its stake in shares of Invivyd by 46.7% in the 3rd quarter. Vanguard Group Inc. now owns 5,762,894 shares of the company’s stock worth $6,339,000 after purchasing an additional 1,834,970 shares during the period. Institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.